Moleculin Biotech, Inc. (NASDAQ: MBRX) announced results from its recent special shareholder meeting via a U.S. Securities and Exchange Commission (SEC) filing. Shareholders approved the exercise of 6,367,956 warrants, marking the largest such action from warrants issued on February 20, 2026.
Warrant Exercise Details
The approved warrants included 854,036 ordinary shares, 211,394 preferred shares, and 7,489 founder shares. Brokers exercised 1,310,070 shares. The exercise price stood at $2.44 per share, reflecting an 88% premium over the one-year low and 80% above the six-month low.
Before the exercise, outstanding voting shares totaled 4,933,110. The transaction adjusted direct ownership by 2,382,989 shares, maintaining accurate share counts.
Name Change Proposal Denied
Shareholders rejected a proposal to rename the company from Moleculin Biotech, Inc. to Moleculin Inc. Ordinary shares rose by 2,015,174, preferred shares by 82,841, and founder shares by 284,974. Nasdaq inquired about the delay, with shareholders citing the need for required procedures. The company received 616,186 ordinary shares, 169,854 preferred shares, 286,879 founder shares, and 1,310,070 broker shares.
Clinical Trial Progress
Moleculin recently submitted its 45th IND amendment to advance the Phase 2/3 MIRACLE trial evaluating Annamycin combined with cytarabine for relapsed or refractory acute myeloid leukemia (AML). Interim data revealed complete response rates 67% higher than cytarabine monotherapy. Among the first 30 patients, 40% achieved complete responses.
The company anticipates topline interim data in mid-2026. CEO Walter Klemp highlighted positive interim results and momentum toward a pivotal FDA meeting.
Separately, Moleculin disclosed collaborations yielding approximately $8.3 million from warrant sales, underwritten by Roth Capital Partners. Proceeds will fund general corporate purposes and working capital.
